Promethazine is a potent antihistamine and sedative that can be used to treat various medical conditions, such as allergies, motion sickness, and insomnia. As with any medication, determining the right Promethazine dosage is crucial for safe and effective treatment. In this blog post, we'll explore everything medical professionals need to know about Promethazine dosage so they can prescribe it confidently and help their patients find relief from symptoms while avoiding any adverse effects.
Promethazine is an antihistamine and works by blocking the natural chemical histamine that your body makes during an allergic reaction. It also works as an antiemetic to help control nausea and vomiting. Promethazine comes in tablet, syrup, and suppository form and is usually taken orally. The typical adult dose for promethazine is 25 mg twice daily.
Promethazine is an antihistamine and works by blocking histamine receptors. It is commonly used to treat allergies, but can also be used to treat nausea, vomiting, and motion sickness. Promethazine can also be used as a sedative for both adults and children.
The standard recommended Promethazine dosage for different conditions is as follows: For the temporary relief of runny nose and sneezing due to the common cold, hay fever, or upper respiratory allergies: Adults and children 12 years of age and older—25 mg (Promethazine HCl) tablet, orally every 4 to 6 hours as needed. Children 6 to 11 years of age—12.5 mg (Promethazine HCl) tablet, orally every 4 to 6 hours as needed. For preoperative sedation in children: Children 2 years of age and older—Dose is based on body weight and must be determined. The usual dose is 0.5 mg per pound (0.23 mg per kg) of body weight injected into a vein or muscle no more often than once every four hours, not to exceed 40 mg in 24 hours for any child. For motion sickness: Adults and children 12 years of age and older—25 mg taken at bedtime or 6.25 to 12.5 mg taken three times a day as needed. Children 6 to 11 years of age—12.5 mg taken at bedtime or 3.125 to 6.25 mg taken three times a day as needed. For nausea and vomiting associated with cancer chemotherapy: Adults and children 16 years of age and older—25 mg injected slowly into a vein over 10 minutes two or three times daily, starting within 30 minutes before.
The most common side effects of Promethazine are: Drowsiness, Dizziness, Nausea and vomiting, Constipation, Blurred vision, Dry mouth. Less common side effects include:
Allergic reactions (rash, hives, difficulty breathing), Agitation or nervousness, Anxiety, Seizures, Fast or irregular heartbeat, High blood pressure, Fainting. Rare side effects include: Toxicology studies in animals have revealed evidence of embryotoxicity, fetotoxicity, and teratogenicity. These effects were noted at doses of 10-15 times the maximum recommended human dose (MRHD) of 25 mg/day. In rats and rabbits, respectively, these doses produced maternal toxicity (reduced body weight gain), embryo-fetal mortality, and growth retardation. There was no evidence of malformations. No adequate studies have been conducted in animals to determine whether Promethazine has a potential for carcinogenesis or mutagenesis.
Promethazine should not be taken if the patient is allergic to it, has certain medical conditions, or is taking certain other medications. Patients with a known allergy to promethazine should not take the medication. Promethazine should also be avoided in patients with liver disease, as it can increase the risk of liver toxicity. Additionally, promethazine should not be taken by pregnant women or nursing mothers, as it may cause harm to the developing fetus or infant. Finally, patients taking MAO inhibitors or other antipsychotic medications should not take promethazine, as it can interact with these drugs and cause serious side effects.
Promethazine is a medication with many potential uses and benefits but requires careful dosing to ensure safety. Understanding how to properly prescribe the right amount of promethazine for each patient is important to maximize treatment efficacy while avoiding any adverse effects. By following the general recommendations outlined by medical professionals, you can develop an effective plan for safely administering this drug to patients.
1.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
2.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
3.
Recurrent UTIs impact eGFR in children with vesicoureteral reflux
4.
Month-Long Wait Times Caused by US Physician Shortage.
5.
Pharyngoesophageal junction cancer is not a good candidate for endoscopically assisted transoral surgery.
1.
A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities
2.
The Importance of Early Detection in Angiosarcoma: A Story of Survival
3.
Leukemia in Focus: Tools, Trials, and Therapy Strategies for Modern Medical Practice
4.
New Research Advances in the Treatment of Multiple Myeloma and Plasmacytoma
5.
Managing KRAS Inhibitor Toxicities: Focus on Rash and Beyond
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III
4.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation